Skip to main content
Fig. 2 | Virology Journal

Fig. 2

From: Hepatitis B seroconversion revisited: new insights into the natural history of acute hepatitis B virus (HBV) infection from quantitative and highly sensitive assays and novel biomarkers

Fig. 2

Serological and molecular assay profiles for a panel with prolonged but declining surface antigenemia exceeding 6 months (43527-3453) and a panel with progression to chronicity (0994-3457). For seroconverter 43527-3453, HBsAg became undetectable 266 days after the DNA peak and anti-HBs was detected ≥ 10 mIU/ml at day 317. HBV DNA and HBsAg levels remained high in panel 0994-3457 with no detectable anti-HBe or anti-HBs. For comparison purposes, all panels are synchronized relative to the peak HBV DNA level (set at Day 0). For graphing purposes, HBV DNA results detected below the LLOQ (10 IU/ml) were assigned the value of 1.0 IU/ml; undetectable HBV DNA was assigned a value of 0.1 IU/ml. HBV pgRNA results detected below the LLOQ (44.7 U/ml) were assigned the value of 2 U/ml; undetectable pgRNA was assigned the value of 1 U/ml. HBcrAg values below the measuring range of the assay were assigned the value of 1 U/ml. Results are considered reactive as follows: Quantitative HBsAg ≥ 0.05 IU/ml, HBsAgNx S/CO ≥ 1.0, Quantitative HBeAg ≥ 0.28 IU/ml, anti-HBs ≥ 10 mIU/ml. HBV pgRNA results for panel 0994-3457 were reported elsewhere [8]

Back to article page

Virology Journal

ISSN: 1743-422X